Potassium%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an essential electrolyte that plays a crucial role in cellular function, nerve impulse transmission, and muscle contraction. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Potassium replacement in patients with significant losses due to diuretics, vomiting, diarrhea, or inadequate dietary intake. ## Adult Dosing * **Oral:** * **Prevention of hypokalemia:** 20 mEq (1.5 g) daily. * **Treatment of hypokalemia:** Typically 40-100 mEq (3-7.5 g) daily, divided into 2-5 doses. Maximum daily dose is generally considered 200 mEq (15 g). Dosing must be individualized based on serum potassium levels and clinical assessment. * **Intravenous (IV):** * **Mild to moderate hypokalemia:** 10-20 mEq (0.75-1.5 g) added to a large volume IV fluid (e.g., 1 L) infused over 2-4 hours. * **Severe hypokalemia or cardiac arrhythmias:** Doses may be higher (e.g., 20-40 mEq [1.5-3 g]) and infused more rapidly (e.g., over 1-2 hours), but *only* under continuous cardiac monitoring. * **Maximum infusion rate:** Generally limited to 10-20 mEq/hour (0.75-1.5 g/hour) peripherally and up to 40 mEq/hour (3 g/hour) centrally, depending on local protocol and patient status, to prevent cardiac arrhythmias and phlebitis. * **Maximum concentration:** Typically 40 mEq/L (3 g/L) peripherally and up to 80 mEq/L (6 g/L) centrally, again depending on local protocol and site of administration. ## Pediatric Dosing * **Oral:** Recommended daily allowance varies by age, generally 1-3 mEq/kg/day (0.075-0.225 g/kg/day). Maximum daily dose should not exceed 100 mEq (7.5 g). * **Intravenous (IV):** Dosing is highly individualized based on serum potassium, clinical status, and electrolyte losses. Typical maintenance is 1-2 mEq/kg/day (0.075-0.15 g/kg/day). Correction of hypokalemia may require higher doses (e.g., up to 0.5 mEq/kg/hour [0.037 g/kg/hour] with continuous ECG monitoring), not to exceed a total daily dose of 3-4 mEq/kg/day (0.225-0.3 g/kg/day). Exact dosing should follow established pediatric protocols. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Dose reductions are necessary. Monitor serum potassium closely. IV administration should be done at slower rates and lower concentrations. * **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes closely. ## Contraindications * Hyperkalemia. * Conditions leading to sustained high levels of potassium, such as untreated Addison's disease, severe renal impairment, or anuria. * Patients with a history of gastrointestinal obstruction or delayed gastric emptying (for oral forms). * Known hypersensitivity to potassium chloride. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence (oral). Phlebitis, pain at injection site (IV). * **Serious:** Hyperkalemia (manifesting as muscle weakness, fatigue, paresthesias, confusion, arrhythmias, cardiac arrest), cardiac conduction abnormalities, gastrointestinal ulceration or bleeding (especially with rapid release oral forms or in patients with slow GI transit). ## Key Drug Interactions * **Potassium-sparing diuretics** (e.g., spironolactone, amiloride, triamterene), **ACE inhibitors**, **ARBs**, **NSAIDs**, **heparin**, **tacrolimus**, **cyclosporine:** Increased risk of hyperkalemia. * **Salt substitutes:** Often contain potassium chloride, increasing the risk of hyperkalemia. * **Cholestyramine:** Can bind potassium in the GI tract, potentially reducing absorption and leading to hypokalemia (though also used to treat hyperkalemia by binding potassium). ## Monitoring * **Serum potassium levels:** Regularly, especially during initiation, dose changes, and in patients with risk factors for hyperkalemia or hypokalemia. Frequency depends on severity of deficit and clinical status. * **Renal function (BUN, creatinine):** Essential, particularly in patients with impaired renal function. * **ECG:** In patients receiving IV potassium, especially rapid infusions or those with severe hypokalemia or risk of cardiac events. * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral potassium chloride tablets and capsules should be taken with a full glass of water to minimize GI irritation and the risk of esophageal or gastric ulceration. * Liquid formulations can be diluted in juice or water to improve taste and tolerance. * Extended-release formulations may reduce GI side effects but can lead to pill impaction if not taken with sufficient fluid. * IV potassium is a vesicant; extravasation can cause severe tissue damage. * Always verify concentration and infusion rate for IV potassium chloride carefully, as errors can be life-threatening. * Hypokalemia can potentiate digitalis toxicity. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date drug details.